Skip to main content

Advertisement

Table 2 Studies of flow-mediated dilatation in systemic sclerosis

From: Cardiovascular disease in systemic sclerosis - an emerging association?

Reference Total SSc number lSSc number dSSc number Controls number Outcomea Other findings
Lekakis et al. [40], 1998 12 0 12 12 NMD ↓. Improvement was found in FMD after estrogen administration.
Andersen et al. [44], 2002 24 20 4 24 NMD ↔
D'Andrea et al. [42], 2007 33 18 15 33 NMD ↔. FMD was a predictor of middle LV strain on TTE.
Szucs et al. [28], 2007 29 19 10 29 NMD ↔
Sfikakis et al. [39], 2007 24 6 18 52 NMD ↔. Four weeks of bosentan led to improvement in FMD.
Bartoli et al. [38], 2007 35 24 11 20 No correlation between FMD and cardiovascular risk factors was found.
Roustit et al. [27], 2008 42 33 9 33 NMD ↔
Cypiene et al. [37], 2008 17 0 17 34 NMD ↔
Rollando et al. [43], 2010 43 30 13 27 FMD was inversely correlated with microvascular damage on nailfold videocapillaroscopy.
Rossi et al. [45], 2010 14 10 4 14 NMD ↓
  1. aFlow-mediated dilatation (FMD) in patients with systemic sclerosis (SSc) relative to controls: ↓, lower in patients with SSc than controls; ↔, no difference between patients with SSc and controls. dSSc, diffuse systemic sclerosis; lSSc, limited systemic sclerosis; LV, left ventricle; NMD, nitroglycerin-mediated dilatation; TTE, trans-thoracic echocardiography.